Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two …
The Lancet, 2022•thelancet.com
Background Faricimab is a bispecific antibody that acts through dual inhibition of both
angiopoietin-2 and vascular endothelial growth factor A. We report primary results of two
phase 3 trials evaluating intravitreal faricimab with extension up to every 16 weeks for
neovascular age-related macular degeneration (nAMD). Methods TENAYA and LUCERNE
were randomised, double-masked, non-inferiority trials across 271 sites worldwide.
Treatment-naive patients with nAMD aged 50 years or older were randomly assigned (1: 1) …
angiopoietin-2 and vascular endothelial growth factor A. We report primary results of two
phase 3 trials evaluating intravitreal faricimab with extension up to every 16 weeks for
neovascular age-related macular degeneration (nAMD). Methods TENAYA and LUCERNE
were randomised, double-masked, non-inferiority trials across 271 sites worldwide.
Treatment-naive patients with nAMD aged 50 years or older were randomly assigned (1: 1) …
Background
Faricimab is a bispecific antibody that acts through dual inhibition of both angiopoietin-2 and vascular endothelial growth factor A. We report primary results of two phase 3 trials evaluating intravitreal faricimab with extension up to every 16 weeks for neovascular age-related macular degeneration (nAMD).
Methods
TENAYA and LUCERNE were randomised, double-masked, non-inferiority trials across 271 sites worldwide. Treatment-naive patients with nAMD aged 50 years or older were randomly assigned (1:1) to intravitreal faricimab 6·0 mg up to every 16 weeks, based on protocol-defined disease activity assessments at weeks 20 and 24, or aflibercept 2·0 mg every 8 weeks. Randomisation was performed through an interactive voice or web-based response system using a stratified permuted block randomisation method. Patients, investigators, those assessing outcomes, and the funder were masked to group assignments. The primary endpoint was mean change in best-corrected visual acuity (BCVA) from baseline averaged over weeks 40, 44, and 48 (prespecified non-inferiority margin of four letters), in the intention-to-treat population. Safety analyses included patients who received at least one dose of study treatment. These trials are registered with ClinicalTrials.gov (TENAYA NCT03823287 and LUCERNE NCT03823300).
Findings
Across the two trials, 1329 patients were randomly assigned between Feb 19 and Nov 19, 2019 (TENAYA n=334 faricimab and n=337 aflibercept), and between March 11 and Nov 1, 2019 (LUCERNE n=331 faricimab and n=327 aflibercept). BCVA change from baseline with faricimab was non-inferior to aflibercept in both TENAYA (adjusted mean change 5·8 letters [95% CI 4·6 to 7·1] and 5·1 letters [3·9 to 6·4]; treatment difference 0·7 letters [−1·1 to 2·5]) and LUCERNE (6·6 letters [5·3 to 7·8] and 6·6 letters [5·3 to 7·8]; treatment difference 0·0 letters [–1·7 to 1·8]). Rates of ocular adverse events were comparable between faricimab and aflibercept (TENAYA n=121 [36·3%] vs n=128 [38·1%], and LUCERNE n=133 [40·2%] vs n=118 [36·2%]).
Interpretation
Visual benefits with faricimab given at up to 16-week intervals demonstrates its potential to meaningfully extend the time between treatments with sustained efficacy, thereby reducing treatment burden in patients with nAMD.
Funding
F Hoffmann-La Roche.
thelancet.com
